Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients

BACKGROUND: Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we sought to describe the 5-year safety profile of maraviroc. METHODS: Two large phase 3 studies of maraviroc enrolled HIV-infected...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulick, Roy M., Fatkenheuer, Gerd, Burnside, Robert, Hardy, W. David, Nelson, Mark R., Goodrich, James, Mukwaya, Geoffrey, Portsmouth, Simon, Heera, Jayvant R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2014
Materias:
Brief Report: Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893710/
https://www.ncbi.nlm.nih.gov/pubmed/24419064
http://dx.doi.org/10.1097/QAI.0b013e3182a7a97a
Descripción
Sumario:BACKGROUND: Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we sought to describe the 5-year safety profile of maraviroc. METHODS: Two large phase 3 studies of maraviroc enrolled HIV-infected treatment-experienced patients and followed them up for 5 or more years. Survival and selected clinical end points were identified and assessed. RESULTS: A total of 938 enrolled patients received maraviroc-containing regimens. Rates of death and selected clinical events (eg, hepatic failure, malignancy, and myocardial infarction) were low during follow-up. CONCLUSIONS: Maraviroc was generally safe in treatment-experienced participants for >5 years.

Ejemplares similares